| Publications | PubMed=7175440; DOI=10.1084/jem.156.6.1755
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
J. Exp. Med. 156:1755-1766(1982) PubMed=6864164; DOI=10.1084/jem.158.1.53
Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J.
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983) PubMed=2983346; DOI=10.1073/pnas.82.5.1470
Dracopoli N.C., Houghton A.N., Old L.J.
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985) PubMed=2453881; DOI=10.1073/pnas.85.11.3965
Real F.X., Furukawa K.S., Mattes M.J., Gusik S.A., Cordon-Cardo C., Oettgen H.F., Old L.J., Lloyd K.O.
Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein.
Proc. Natl. Acad. Sci. U.S.A. 85:3965-3969(1988) PubMed=7509835; DOI=10.1111/1523-1747.ep12371784
Bouchard B., Vijayasaradhi S., Houghton A.N.
Production and characterization of antibodies against human tyrosinase.
J. Invest. Dermatol. 102:291-295(1994) PubMed=7747814
Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H., Cordon-Cardo C., Kamb A.
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Am. J. Pathol. 146:1199-1206(1995) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=9692547; DOI=10.1038/sj.onc.1201881
Tsao H., Zhang X., Benoit E., Haluska F.G.
Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.
Oncogene 16:3397-3402(1998) PubMed=10766161
Tsao H., Zhang X., Fowlkes K., Haluska F.G.
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Cancer Res. 60:1800-1804(2000) PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004) PubMed=21725359; DOI=10.1038/onc.2011.250
Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B.
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625
Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B.
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Cancer Res. 74:2340-2350(2014) |
|---|
